Compare BFLY & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFLY | DBVT |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | United States | France |
| Employees | 220 | 90 |
| Industry | Medical Electronics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 948.8M |
| IPO Year | N/A | 2014 |
| Metric | BFLY | DBVT |
|---|---|---|
| Price | $7.61 | $15.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $5.00 | ★ $32.04 |
| AVG Volume (30 Days) | ★ 11.2M | 300.6K |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,636,000.00 |
| Revenue This Year | $24.01 | $35.04 |
| Revenue Next Year | $19.93 | $2,360.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 35.77 |
| 52 Week Low | $1.32 | $8.51 |
| 52 Week High | $9.69 | $26.19 |
| Indicator | BFLY | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 58.41 | 41.15 |
| Support Level | $3.83 | $12.63 |
| Resistance Level | $9.48 | $17.78 |
| Average True Range (ATR) | 0.86 | 1.07 |
| MACD | 0.07 | 0.08 |
| Stochastic Oscillator | 53.92 | 20.55 |
Butterfly Network Inc is a digital health business transforming care with handheld, whole-body ultrasound. Powered by its proprietary Ultrasound-on-Chip technology, its solution enables the acquisition of imaging information from an affordable, powerful device that fits in a healthcare professional's pocket with a combination of cloud-connected software and hardware technology that is easily accessed through a mobile application. Butterfly iQ+ is an ultrasound device that can perform whole-body imaging in a single handheld probe using semiconductor technology. The company operates in one reportable segment, which includes all activities related to the development, manufacture, and sale of the Company's products, software, and other services.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.